DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
CERC-501 is an investigational drug.
There have been 7 clinical trials for CERC-501. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Case Western Reserve University.
There are six US patents protecting this investigational drug and seventy international patents.
Recent Clinical Trials for CERC-501
|Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury||Aevi Genomic Medicine, LLC, a Cerecor company||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Cerecor Inc||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||National Institute on Drug Abuse (NIDA)||Phase 2|
Top disease conditions for CERC-501
Top clinical trial sponsors for CERC-501
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CERC-501||Get Started Free||Heteroarylphenoxy benzamide kappa opioid ligands||Pfizer Inc. (New York, NY)||Get Started Free|
|CERC-501||Get Started Free||Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features||H. LUNDBECK A/S (Valby, DK)||Get Started Free|
|CERC-501||Get Started Free||Methods of treating pancreatic cancer using GPCR antagonists||CITY OF HOPE (Duarte, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CERC-501||Australia||AU2017365123||2036-11-28||Get Started Free|
|CERC-501||Canada||CA3045242||2036-11-28||Get Started Free|
|CERC-501||China||CN110234638||2036-11-28||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|